These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 18004210)

  • 1. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
    Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T
    Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
    Gurbel PA; Bliden KP; Antonino MJ; Stephens G; Gretler DD; Jurek MM; Pakyz RE; Shuldiner AR; Conley PB; Tantry US
    J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.
    Peace AJ; Mangiacapra F; Bailleul E; Delrue L; Dierickx K; Conte M; Puymirat E; Fraeymans AL; Meeus P; Bartunek J; Volpe M; Barbato E
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1314-9. PubMed ID: 24723553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.
    Malek LA; Kisiel B; Spiewak M; Grabowski M; Filipiak KJ; Kostrzewa G; Huczek Z; Ploski R; Opolski G
    Circ J; 2008 Jul; 72(7):1165-9. PubMed ID: 18577829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
    Ford NF
    J Clin Pharmacol; 2009 May; 49(5):506-12. PubMed ID: 19246723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
    Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R
    Platelets; 2012; 23(8):586-93. PubMed ID: 22390861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
    Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
    Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.